One is the already mentioned study with the dual EGFR/HER2 inhibitor lapatinib.[13] This study, conducted in anthracycline and taxane pre-treated HER2-positive advance breast cancer patients whose disease was clinically resistant to trastuzumab, was closed after the first interim analysis reporting an about 50% reduction in the risk of relapse for patients receiving lapatinib plus capecitabine, compared with capecitabine alone. This evidence concerns the gene EGFR and breast carcinoma.